Literature DB >> 16032279

Chemical analgesia for velvet antler removal in deer.

V P Walsh1, P R Wilson.   

Abstract

There is a legal requirement to provide analgesia for velvet antler removal in New Zealand. Currently, this is achieved using local anaesthetic blockade, with or without systemically administered sedative/analgesic agents, or by compression in 1-year-old stags. Lignocaine hydrochloride 2% is most commonly used and is most effective when administered as a high-dose ring block. Combinations of various amino-amide local anaesthetic agents can achieve rapid onset and prolonged duration of analgesia, though concerns about drug residues and carcinogenic potential of a lignocaine metabolite have led to consideration of the amino-ester family of local anaesthetics as alternatives. Systemically administered analgesics, including opioids, alpha-2-adrenergic agents and ketamine provide dose-dependent sedation and analgesia. However, none are sufficient, alone or in combination, to produce surgical analgesia at currently recommended dose rates and when reversal agents are given, analgesic effects are usually reversed as well as sedation. Thus, local anaesthetic blockade is still indicated, though the potential for drug or drug-metabolite residues in velvet antler remains a concern. The need for and effectiveness of non-steroidal anti-inflammatory drugs (NSAIDs) for post-operative analgesia requires investigation. Amitriptyline, locally administered opioid agonists, tramadol and other systemically administered agents may warrant future investigation for surgical and post-operative analgesia for velvet antler removal.

Entities:  

Year:  2002        PMID: 16032279     DOI: 10.1080/00480169.2002.36319

Source DB:  PubMed          Journal:  N Z Vet J        ISSN: 0048-0169            Impact factor:   1.628


  1 in total

1.  Sika deer antler as a novel model to investigate dental implant healing: A pilot experimental study.

Authors:  Yun He; Dominik Fischer; Istabrak Hasan; Werner Götz; Ludger Keilig; Luisa Ziegler; Markus Abboud; Christoph Bourauel; Gerhard Wahl
Journal:  PLoS One       Date:  2018-07-31       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.